Sherif Amin – Country President, Novartis Egypt
Sherif Amin, an 18-year industry veteran with 12 years of experience in oncology leadership roles across MEA, is the recipient of several awards, including the 2019 Oncology President Award, 2015…
In Egypt, Novartis has been present for more than 52 years. Novartis Technical Operations, Cairo site manufactures for Pharma, Sandoz locally and provides additional capacity within Novartis’ global manufacturing and supply network (export business) . The manufacturing plant is situated in Al-Amiria District, Cairo. Total site size is 80’000 Sq m including all the necessary infrastructure.
Contact
3 El Sawah St. – EL Amiria, Cairo
Tel: +20 2 22861000
Website: https://www.novartis.com.eg
Sherif Amin, an 18-year industry veteran with 12 years of experience in oncology leadership roles across MEA, is the recipient of several awards, including the 2019 Oncology President Award, 2015…
Basyouni Abuseif, country president and CPO Head at Novartis Egypt, explains how the Swiss company has taken over the leadership position in the Egyptian pharmaceutical market despite economic and political…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active…
In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis…
In a milestone for global health, Novartis has received Swissmedic approval for Coartem Baby, the world’s first antimalarial treatment tailored for newborns and infants under 4.5kg. The decision fills a…
Over the past decade, Dr Lutz Hegemann has helped transform Novartis’ Global Health unit into a strategic pillar that bridges innovation with real-world access. Rather than focusing on visibility, the…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’…
Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
See our Cookie Privacy Policy Here
